[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 720
6. Park WS, Cho YG, Kim CJ, Song JH, Lee YS, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY: Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med; 2005 Aug 31;37(4):276-81
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of the RUNX3 gene in hepatocellular carcinoma.
  • To elucidate the potential etiological role of the RUNX3 gene in the development of hepatocellular carcinoma (HCC), we have analyzed the methylation status of 5' CpG island of the RUNX3 gene in a series of 73 HCC tissues and 11 liver cell lines.
  • Expectedly, promoter methylation of RUNX3 gene was found in 2 (2.7%) of 73 corresponding normal liver, whereas 30 (41.1%) of 73 HCCs and 4 (40%) of 10 liver cancer cell lines showed hypermethylation of the gene, respectively.
  • There was no significant difference between promoter hypermethylaion and clinicopathologic parameters of primary HCC samples, including histologic grade, microvascular invasion, and clinical stage.
  • Interestingly, demethylating agent 5-aza-2-deoxycytidine induced reactivation and more potent expression of RUNX3 gene in HCC cell lines.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA Methylation. DNA, Neoplasm / metabolism. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Male. Middle Aged. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155404.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


7. Park JW: [Hepatocellular carcinoma in Korea: introduction and overview]. Korean J Gastroenterol; 2005 Apr;45(4):217-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatocellular carcinoma in Korea: introduction and overview].
  • Hepatocellular carcinoma (HCC) is a highly malignant, generally fatal neoplasm arising from hepatocytes.
  • HCC accounts for over 80% of all primary liver cancers which ranks fourth among the organ-specific causes of cancer-related deaths worldwide.
  • Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) or presence of liver cirrhosis are important risk factors for HCC development globally.
  • Recently, five year survival rate of primary liver cancer is 9.6% in Korea.
  • Such poor prognosis of HCC results from the late detection of cancer, an aggressive tumor biology and underlying chronic liver diseases.
  • Because almost eighty percent of HCC is diagnosed in late stage, we launched a nationwide surveillance program to screen high risk groups (HBV or HCV carriers or liver cirrhosis, over 40 years old) and formulated the Korean practice guideline for the diagnosis and treatment of HCC with special emphasis on advanced stage of HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Korea / epidemiology. Male. Middle Aged. Prevalence. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843747.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


8. Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D'Angelica M, Abou-Alfa G, Blumgart LH, DeMatteo RP: Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer; 2006 Mar 15;106(6):1331-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with fibrolamellar hepatocellular carcinoma.
  • BACKGROUND: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare variant of hepatocellular carcinoma, has distinct pathologic features, and typically occurs in young patients without underlying hepatitis or cirrhosis.
  • Twenty-eight patients with primary disease underwent complete gross resection, and 13 patients were unresectable.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Fibrolamellar carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16475212.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Tsai S, Gurakar A, Anders R, Lam-Himlin D, Boitnott J, Pawlik TM: Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature. Dig Dis Sci; 2010 Nov;55(11):3052-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature.
  • BACKGROUND: Alagille syndrome is a multi-system developmental disorder associated with paucity of interlobular bile ducts and cholestasis, rarely associated with hepatocellular carcinoma.
  • As such, we herein review the modern management of a large hepatocellular carcinoma in an adult patient with Alagille syndrome and review the literature of adult Alagille patients with hepatocellular carcinoma.
  • CASE PRESENTATION: A 29-year-old woman with a history of Alagille syndrome was referred with biopsy-proven 12 × 8 cm hepatocellular carcinoma replacing her right liver.
  • Biopsy of the contralateral liver demonstrated findings consistent with Alagille syndrome, but no underlying cirrhosis.
  • CT volumetrics demonstrated a future liver remnant of 40%.
  • [MeSH-major] Alagille Syndrome / epidemiology. Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / epidemiology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Comorbidity. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed


10. Salguero FJ, Richard A, Gough J, Long A, Weyer U, Cooley WA, Chambers MA, Lesellier S: Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles). J Comp Pathol; 2010 Feb-Apr;142(2-3):208-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles).
  • A mass was identified within the left lateral lobe of the liver of a 10-year-old Eurasian badger (Meles meles).
  • The histological appearance was consistent with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / veterinary. Liver / pathology. Liver Neoplasms / veterinary. Mustelidae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19683720.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Echejoh GO, Tanko MN, Manasseh AN, Ogala-Echejoh S, Ugoya SO, Mandong BM: Hepatocellular carcinoma in Jos, Nigeria. Niger J Med; 2008 Apr-Jun;17(2):210-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in Jos, Nigeria.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is the most common abdominal malignancy, representing 80-90% of primary liver malignancies around the world.
  • RESULTS: A total of 71 cases of HCC (31.3% of 227 liver biopsies in the same period) were diagnosed within the 10-year period.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Nigeria / epidemiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18686842.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


12. Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW: Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today; 2006;36(10):892-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
  • PURPOSE: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary hepatic neoplasm (PHN) with features of both hepatocellular and biliary differentiation.
  • We compared the outcome of hepatic resection in patients with HCC-CC, those with hepatocellular carcinoma (HCC), and those with cholangiocarcinoma (ICC).
  • The prevalence of underlying liver cirrhosis was significantly lower in the ICC group (7.8%) than in the HCC (49%) and HCC-CC (41.5%) groups (P < 0.0001).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998683.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Borzio M, Colloredo G, Pioltelli P, Quagliuolo M, Gruppo Epatologico Lombardo (GEL): Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis; 2007 Nov;39(11):1011-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and outcome of hepatocellular carcinoma in Lombardy.
  • BACKGROUND AND AIMS: Information on the impact of therapeutic strategies of hepatocellular carcinoma is still incomplete due to the lack of surveys involving primary-care centres.
  • PATIENTS AND METHODS: The Gruppo Epatologico Lombardo (GEL) carried out a study on 361 incident hepatocellular carcinoma observed from January to December 1998 in 22 hospitals in Lombardy.
  • Hepatocellular carcinoma was multifocal/diffuse (more than three nodules) in 91 (25%), less than three nodules in 86 (24%) and monofocal in 184 (51%) (</=3cm in 146).
  • As to the therapy: 145 hepatocellular carcinomas (40%) were untreated, 78 (22%) underwent percutaneous ethanol injection/radiofrequency ablation, 75 (20%) transarterial chemoembolization, 32 (9%) liver resection and 3 (0.8%) ortothopic liver transplantation (OLT).
  • CONCLUSION: This prospective, region-wide, cohort study showed that the characteristics of hepatocellular carcinoma in Lombardy (1998) do not differ from those reported in previous Italian surveys.
  • Although most hepatocellular carcinomas were discovered at a relatively early stage, a large part remained untreated and the overall prognosis was poor.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / epidemiology. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Italy / epidemiology. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936698.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


1
Advertisement
4. Yuen MF, Hou JL, Chutaputti A, Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma: Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol; 2009 Mar;24(3):346-53
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in the Asia pacific region.
  • Primary liver cancer, particularly hepatocellular carcinoma (HCC) remains a significant disease worldwide.
  • In spite of advances in surgery, liver transplantation and newer pharmaco/biological therapies, the survival rate has improved only slightly over recent decades, and this could be attributable to earlier diagnosis ('lead-time bias').
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Asia / epidemiology. Asian Continental Ancestry Group. Female. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / epidemiology. Humans. Incidence. Male. Middle Aged. Odds Ratio. Prevalence. Prognosis. Risk Assessment. Risk Factors. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220670.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Number-of-references] 35
  • [Investigator] Farrell GC; Chan HL; Yuen MF; Amarapurkar DN; Chutaputti A; Fan JG; Hou JL; Han KH; Kao JH; Lim SG; Mohamed R; Sollano J; Ueno Y
  •  go-up   go-down


15. Liang WC, Guo RP, Chen MS, Long H, Shi M, Wei W, Zhang YQ: [Efficacy of pulmonary resection for primary hepatocellular carcinoma patients with pulmonary metastasis]. Ai Zheng; 2008 Mar;27(3):319-22
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of pulmonary resection for primary hepatocellular carcinoma patients with pulmonary metastasis].
  • This study was to evaluate the efficacy of pulmonary resection for primary hepatocellular carcinoma (HCC) patients with pulmonary metastasis.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334126.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Deutsch M, Papatheodoridis GV, Tzakou A, Hadziyannis SJ: Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol; 2008 Jan;20(1):5-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis.
  • OBJECTIVES: In primary biliary cirrhosis (PBC), the development of hepatocellular carcinoma (HCC) was thought to represent a rare complication.
  • The risk of extrahepatic malignancies is higher than that of HCC, but it is not influenced by the histologic stage of the liver disease.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Liver Cirrhosis, Biliary / complications. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / etiology. Cohort Studies. Disease Progression. Female. Follow-Up Studies. Genital Neoplasms, Female / etiology. Greece / epidemiology. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Primary biliary cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Gastroenterol Hepatol. 2008 Jan;20(1):1-4 [18090981.001]
  • (PMID = 18090982.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Choi BO, Jang HS, Kang KM, Lee SW, Kang YN, Chai GY, Choi IB: Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol; 2006 Mar;36(3):154-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma.
  • OBJECTIVE: The purpose of our study was to evaluate the feasibility and treatment outcomes of fractionated stereotactic radiotherapy (SRT) for primary hepatocellular carcinoma (HCC).
  • CONCLUSION: These results suggest that fractionated SRT is a relatively safe and effective method for treating small primary HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Dose Fractionation. Liver Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520355.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Nan KJ, Guo H, Ruan ZP, Jing Z, Liu SX: Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma. World J Gastroenterol; 2005 Feb 28;11(8):1237-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma.
  • AIM: To investigate the expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma (HCC).
  • METHODS: Expression of p57(kip2), PCNA and p53 in tumor tissues from 32 patients with HCC and 10 liver tissues of normal persons was detected with Elivision immunohistochemical technique.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Nuclear Proteins / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Apoptosis / physiology. Cyclin-Dependent Kinase Inhibitor p57. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754413.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / Nuclear Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC4250722
  •  go-up   go-down


19. Bao ST, Gui SQ, Lin MS: Relationship between expression of Smac and Survivin and apoptosis of primary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int; 2006 Nov;5(4):580-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between expression of Smac and Survivin and apoptosis of primary hepatocellular carcinoma.
  • However, little is known about the clinical significance of Smac/DIABLO in various cancers including hepatocellular carcinoma (HCC).
  • This study was undertaken to investigate the expression of Smac and Survivin and their relationship with the apoptosis in primary HCC.
  • The mRNA expression of Smac and Survivin was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) in HCC tissues of 50 patients, para-carcinoma tissues of 20 patients, and normal liver tissues of 15 patients.
  • RESULTS: Smac mRNA was detected by RT-PCR in HCC tissues of 21 (42.0%) of the 50 patients, para-carcinoma tissues of 19 (95.0%) of the 20 patients, and normal liver tissues of 15 (100%) of the 15 patients.
  • Survivin mRNA was found in HCC tissues of 46 of the 50 patients, para-carcinoma tissues of 2 of the 20 patients, and normal liver tissues of 0 of 15 patients.
  • Immunohistochemistry revealed Smac protein in HCC tissues of 20 patients (40.0%), in para-carcinoma tissues of 18 patients (90.0%), and normal liver tissues of 15 patients (100.0%).
  • Survivin protein was found in HCC tissues in 45 patients, para-carcinoma tissues in 2 patients, and normal liver tissues in none of the patients.
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Hepatocellular / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Liver Neoplasms / metabolism. Microtubule-Associated Proteins / metabolism. Mitochondrial Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Liver / metabolism. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085346.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / DIABLO protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Microtubule-Associated Proteins; 0 / Mitochondrial Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


20. Tezuka M, Hayashi K, Kubota K, Sekine S, Okada Y, Ina H, Irie T: Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma. Dig Dis Sci; 2007 Mar;52(3):783-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma.
  • We compared the growth rate of locally recurrent hepatocellular carcinoma (HCC) with that of primary HCC.
  • The tumor volume doubling time (DT) of locally recurrent HCC was significantly shorter than that of primary HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bromhexine. Chemoembolization, Therapeutic. Female. Humans. Male. Middle Aged. Radiographic Image Enhancement

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268830.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q1J152VB1P / Bromhexine
  •  go-up   go-down


26. Zhong XG, He S, Yin W, Deng JY, Chen B: [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro]. Zhonghua Gan Zang Bing Za Zhi; 2005 Sep;13(9):644-7
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro].
  • OBJECTIVE: To explore the biological behavior of adult liver stem cells in a co-cultured system of them with hepatocellular carcinoma (HCC) cells without direct contact between the two kinds of cells.
  • METHODS: WB-F344, a kind of rat adult liver stem cell, and rat embryonic fibroblasts (REF) from a primary culture were engineered to express enhanced green fluorescent protein (EGFP) by recombinant adenoviral-mediated methods.
  • After the HCC cells grew to 40%-60% confluence in the culture dish with a 10-mm cell-free area, a similar number of WB-EGFP and REF-EGFP were placed in the blank areas respectively.
  • Their appearance was found not only when WB-EGFP cells were seeded into the cell-free area at the center of the dish, but also when seeded into the blank area at the extreme edge of the plate.
  • CONCLUSIONS: The results mean that adult liver stem cells have a biological behavior of selective tropism toward HCC cells in vitro, and suggest a possibility of using migratory liver stem cells as a delivery vehicle for gene therapy for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver / cytology. Liver Neoplasms / pathology. Stem Cells / cytology

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174449.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Ali S, Shah V: Small-duct primary sclerosing cholangitis with hepatocellular carcinoma requiring liver transplantation. Hepatobiliary Pancreat Dis Int; 2010 Apr;9(2):208-12
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-duct primary sclerosing cholangitis with hepatocellular carcinoma requiring liver transplantation.
  • BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease, which usually affects young adults and is diagnosed by cholangiography.
  • METHODS: A 31-year-old man presented with severe hematemesis secondary to liver cirrhosis.
  • Over a course of 8 years, his liver decompensated and required an orthotopic liver transplantation.
  • RESULTS: The patient's explanted liver showed changes of PSC affecting only the small- and medium-sized bile ducts in addition to three incidental nodules of hepatocellular carcinoma.
  • CONCLUSIONS: Small-duct PSC has a substantially better prognosis than the large-duct type, with less chance of developing cirrhosis and an equal risk for developing hepatocellular carcinoma, but no increased risk for developing cholangiocarcinoma.
  • Liver transplantation remains the ultimate cure.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Cholangitis, Sclerosing / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Humans. Male


28. Shah S, Gupta S, Shet T, Maheshwari A, Wuntkal R, Mohandas KM: Metastatic clear cell variant of hepatocellular carcinoma with an occult hepatic primary. Hepatobiliary Pancreat Dis Int; 2005 May;4(2):306-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic clear cell variant of hepatocellular carcinoma with an occult hepatic primary.
  • Metastatic clear cell carcinomas are commonly seen in the kidney and lung.
  • Clear cell variant of hepatocellular carcinoma is an uncommon tumour.
  • In this unusual case of metastatic clear cell carcinoma presenting as Sister Mary Joseph's nodule, no primary evidence was observed radiologically in the liver, but the level of alfa fetoprotein was markedly elevated.
  • Metastatic clear cell carcinoma of the liver with an occult hepatic primary was diagnosed by immunohistochemical profile of the tumour.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasms, Second Primary / pathology. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908336.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


29. Batsis JA, Halfdanarson TR, Pitot H: Extra-hepatic hepatocellular carcinoma presenting as obstructive jaundice. Dig Liver Dis; 2006 Oct;38(10):768-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-hepatic hepatocellular carcinoma presenting as obstructive jaundice.
  • Hepatocellular carcinoma is a neoplasm with a uniformly poor prognosis.
  • Risk factors for its development include chronic hepatitis B or C infection, haemochromatosis and alpha-1-antitrypsin deficiency, but individuals with any type of chronic liver disease are predisposed.
  • We present a patient with notable atypical clinical features for hepatocellular carcinoma.
  • The patient had neither predisposing risk factors nor a primary liver lesion causing obstructive jaundice.
  • Hepatocellular carcinoma generally requires a surgical cure, but patients who are icteric often portend poorer prognoses.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Jaundice, Obstructive / etiology. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Lymphatic Diseases / etiology. Male

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243009.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


30. Ryu HS, Hwang ET, Choi CS, Kim TH, Kim HC, Yun KJ, Park DE: [A case of hepatocellular carcinoma invading the gallbladder misdiagnosed as a primary gallbladder carcinoma]. Korean J Hepatol; 2009 Mar;15(1):80-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hepatocellular carcinoma invading the gallbladder misdiagnosed as a primary gallbladder carcinoma].
  • Extrahepatic metastasis of hepatocellular carcinoma (HCC) is occasionally seen in the lung, bone, adrenal gland, and lymph nodes.
  • Since there is no peritoneum between the gallbladder and the liver fossa, a gallbladder cancer easily invades the liver; however, HCC seldom invades the gallbladder because it rarely destroys the muscle layer or the collagen fibers of the gallbladder wall.
  • We report here a case of HCC that directly invaded the gallbladder, and that resembled gallbladder carcinoma invading the liver.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Gallbladder Neoplasms / secondary. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346788.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


31. Miyoshi A, Takahashi T, Otsuka T, Kohya N, Miyazaki K: Efficacy of major hepatectomy for large hepatocellular carcinoma. Hepatogastroenterology; 2009 May-Jun;56(91-92):768-72
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of major hepatectomy for large hepatocellular carcinoma.
  • BACKGROUND/AIMS: Large hepatocellular carcinomas (HCC) with diameter >10 cm reportedly displays poor prognosis.
  • METHODOLOGY: From January 1987 to December 2004, a total of 252 patients with primary HCC underwent hepatic resection in our institution.
  • Liver cirrhosis and early recurrence were significantly less frequent in the major hepatectomy group than in the minor hepatectomy group (p=0.026; p=0.005).
  • CONCLUSIONS: Major hepatectomy can improve prognosis while preserving liver function for patients with large HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621699.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


32. Uchiyama K, Ueno M, Hama T, Kawai M, Tani M, Terasawa H, Ozawa S, Uemura R, Nakase T, Yamaue H: Recurrence of primary hepatocellular carcinoma after hepatectomy--differences related to underlying hepatitis virus species. Hepatogastroenterology; 2005 Mar-Apr;52(62):591-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of primary hepatocellular carcinoma after hepatectomy--differences related to underlying hepatitis virus species.
  • METHODOLOGY: The patients who had undergone hepatectomy for primary hepatocellular carcinoma (HCC) over the past 10 years at our hospital were divided into three groups based on their underlying causal diseases: hepatitis B (B type), hepatitis C (C type), and non-viral hepatitis including alcoholic hepatitis, and their backgrounds and long-term results after hepatectomy were comparatively investigated.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Hepatitis B / complications. Hepatitis C / complications. Liver Neoplasms / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Risk Factors


33. Zhang GQ, Wang HB, Gao P, Fang CH, Chen GH: [Relationship of extrahepatic metastasis of primary hepatocellular carcinoma between circulative tumor cells in the blood of hepatoma patients]. Zhonghua Wai Ke Za Zhi; 2009 Dec 15;47(24):1857-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship of extrahepatic metastasis of primary hepatocellular carcinoma between circulative tumor cells in the blood of hepatoma patients].
  • OBJECTIVE: To study the relationship between extrahepatic metastasis of primary hepatocellular carcinoma and circulative tumor cells in the blood of hepatoma patients.
  • METHODS: The immunomagnetic bead technique was employed to enrich and separate the hepatoma cells in the peripheral blood of preoperative and postoperative hepatoma patients.
  • The relationship between postoperative extrahepatic metastasis and hepatoma cells in peripheral blood cancer cells were analyzed.
  • The circulative tumor cells in the peripheral blood of hepatoma patients were enriched and separated by immunomagnetic bead technique.
  • They were identified as hepatoma cells by AFP immunohistochemistry.
  • Among 30 cases of hepatoma patients, the positive rate of hepatoma cells in the peripheral blood of preoperation and postoperation were 53.3% and 83.3% respectively.
  • CONCLUSIONS: Extrahepatic metastasis of primary hepatocellular carcinoma is obviously correlated to the positive tumor cells and the concentration in the peripheral blood of preoperative patients.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193401.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


34. Kannangai R, Sahin F, Torbenson MS: EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol; 2006 Nov;19(11):1456-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR is phosphorylated at Ty845 in hepatocellular carcinoma.
  • Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of hepatocellular carcinomas.
  • Recent studies of EGFR inhibitors to treat hepatocellular carcinoma have been encouraging and better understanding of EGFR signaling may lead to more effective strategies for inhibiting this key pathway.
  • Cell line and animal studies have shown that MAPK and STAT-3 are important mediators of the EGFR signal in liver cells.
  • However, little is known about EGFR phosphorylation and subsequent signaling in primary hepatocellular carcinoma.
  • We investigated the site of EGFR phosphorylation by Western blot in 18 hepatocellular carcinomas.
  • Fourteen of 18 hepatocellular carcinomas had detectable EGFR by Western blotting and 13 of 14 showed phosphorylation at tyrosine 845.
  • These findings were further explored by examination of EGFR expression and signaling pathway activation in tissue arrays comprised of 73 hepatocellular carcinomas using antibodies that recognize phosphorylated (or activated) proteins.
  • We conclude that EGFR is phosphorylated at tyrosine 845 in most hepatocellular carcinomas and that EGFR expression by immunohistochemistry does not correlate well with STAT-3, STAT-5, MAPK, or AKT immunostaining.
  • [MeSH-major] Carcinoma, Hepatocellular / chemistry. Liver Neoplasms / chemistry. Receptor, Epidermal Growth Factor / analysis. Tyrosine / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cell Proliferation. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitogen-Activated Protein Kinase 1 / analysis. Mitogen-Activated Protein Kinase 3 / analysis. Phosphorylation. Proto-Oncogene Proteins c-akt / analysis. STAT3 Transcription Factor / analysis. STAT5 Transcription Factor / analysis. Signal Transduction. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936701.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; 42HK56048U / Tyrosine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


35. Kwon JE, Kim SH, Cho NH: No ancillary finding is valid to distinguish a primary ovarian hepatoid carcinoma from metastatic hepatocellular carcinoma. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1691-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No ancillary finding is valid to distinguish a primary ovarian hepatoid carcinoma from metastatic hepatocellular carcinoma.
  • Primary ovarian hepatoid carcinomas (POHC) are extremely rare.
  • Especially rare are those with phenotypic properties of hepatocellular carcinoma (HCC) and an absence of clinical evidence of hepatic tumor.
  • We report a case of a POHC with a common microscopic, immunophenotypic, and ultrastructural property of HCC in the absence of a liver mass.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884387.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


36. Zhu Lz, Yang Rj: [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage]. Beijing Da Xue Xue Bao; 2008 Apr;40(2):129-34
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Digital subtraction angiography manifestation and interventional therapy of arteriovenous shunting in primary hepatocellular carcinoma of advanced stage].
  • OBJECTIVE: To explore the appearances of digital subtraction angiography (DSA) and therapeutic efficacy of interventional therapy of hepatic carcinoma accompanied with arteriovenous shunting (AVS).
  • METHODS: To retrospectively analyze clinical material of 97 patients with hepatocellular carcinoma with hepatic artery-portal vein shunting(HA-PVS), of whom, 16 had upper gastrointestinal hemorrhage, 51 had middle to large amounts of ascites, and 53 had varices of esophagus and fundus gastricus.
  • CONCLUSION: Primary hepatic carcinoma with AVS increases difficulty of interventional therapyìbut as long as we take active and proper treating measureìwe could acquire satisfactory curative effect without serious syndrome.
  • DSA can demonstrate the type, the site and the degree of AVS completely and directly, thus having important value in treating primary hepatic carcinoma and improving prognosis.
  • [MeSH-major] Angiography, Digital Subtraction. Arteriovenous Fistula / radiography. Arteriovenous Fistula / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / radiography. Female. Hepatic Artery / abnormalities. Humans. Male. Middle Aged. Portal Vein / abnormalities. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458684.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. Chen F, Sato K, Fujinaga T, Sonobe M, Shoji T, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Date H: Pulmonary resection for metastases from hepatocellular carcinoma. World J Surg; 2008 Oct;32(10):2213-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection for metastases from hepatocellular carcinoma.
  • BACKGROUND: Pulmonary metastasectomy has become the standard therapy for various metastatic malignancies to the lungs; however, few data have been available about lung metastasectomy for hepatocellular carcinoma.
  • METHODS: Between 1993 and 2005, 12 patients with pulmonary metastases from hepatocellular carcinomas underwent complete pulmonary resection.
  • All patients had undergone curative resection of their primary hepatocellular carcinomas and also had obtained or had obtainable locoregional control of their primaries.
  • Five patients presented recurrences in the remaining liver before pulmonary metastases, but hepatic recurrences at this interval did not affect an overall survival after pulmonary metastasectomies.
  • Two patients had undergone living-related liver transplantation.
  • CONCLUSIONS: Pulmonary metastasectomy for hepatocellular carcinoma in selected patients was well justified when the maximum tumor size was <3 cm.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18668285.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Hu JX, Dai WD, Miao XY, Zhong DW, Liu W, Wei H: Bisegmentectomy VII-VIII for hepatocellular carcinoma in cirrhotic livers. Hepatogastroenterology; 2007 Jul-Aug;54(77):1311-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bisegmentectomy VII-VIII for hepatocellular carcinoma in cirrhotic livers.
  • BACKGROUND/AIMS: Preservation of nontumorous liver parenchyma should be a priority in hepatic surgery in order to avoid the risk of life-threatening liver failure and maximize the possibility of repeat resection.
  • RESULTS: In 23 of 715 patients with primary hepatocellular carcinoma, the tumor was localized in segments VII, VIII and involved with the superior right hepatic vein.
  • No patient had postoperative life-threatening liver failure and there was no postoperative mortality.
  • CONCLUSIONS: Bisegmentectomy VII and VIII is an oncologically radical but parenchyma-preserving liver resection.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Cirrhosis / complications. Liver Neoplasms / complications. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708243.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


39. Huang JH, Wu PH, Gu YK, Zhang FJ, Li CX, Gao F, Zhang L, Fan WJ, Li CJ: [Study on primary hepatocellular carcinoma associated with hypersplenism treated by partial splenic embolization combined with hepatic arterial chemoembolization]. Ai Zheng; 2006 Aug;25(8):1003-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on primary hepatocellular carcinoma associated with hypersplenism treated by partial splenic embolization combined with hepatic arterial chemoembolization].
  • BACKGROUND & OBJECTIVE: 70-90% of patients of primary hepatocellular carcinoma (PHC) are associated with liver cirrhosis, portal hypertension and hypersplenism.
  • The treatment of PHC is usually hampered by low or slow recovery of blood cell counts.
  • RESULTS: Satisfactory effects were achieved in PSE combined with TACE group in terms of correction of blood cell counts compared with cases treated with TACE alone.
  • CONCLUSION: PSE associated with TACE is safe and effective for the treatment of patients with PHC associated with liver cirrhosis, portal hypertension and hypersplenism.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Hypersplenism / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Blood Cell Count. Embolization, Therapeutic / methods. Female. Hepatic Artery. Humans. Iodized Oil. Male. Splenic Artery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965683.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8001-40-9 / Iodized Oil
  •  go-up   go-down


40. Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS: [Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation]. Ai Zheng; 2005 Jul;24(7):827-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation].
  • BACKGROUND & OBJECTIVE: Previously, treatment outcome evaluation of hepatocellular carcinoma (HCC) was focused on cure rate, survival rate, and survival time.
  • Spearman's correlation analysis showed that age, income, liver function, tumor recurrence, and complications were related to the QOL of HCC patients after treatment.
  • The degree of liver function damage, complications, and tumor recurrence were significantly higher in TACE group than in RFA group (P<0.05).
  • CONCLUSIONS: RFA is an effective and micro-invasive treatment for liver cancer.
  • Compare with TACE alone, TACE in combination with RFA may decrease liver function damage and improve QOL of HCC patients.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation. Liver Neoplasms / surgery. Quality of Life
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemoembolization, Therapeutic. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004809.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


41. Yu L, Sloane DA, Guo C, Howell CD: Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol; 2006 Mar;4(3):355-60
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000.
  • BACKGROUND & AIMS: The incidence of primary hepatocellular carcinoma (HCC) is greater in black Americans compared with white Americans.
  • There was no racial difference in the frequency of alcoholic and cryptogenic liver diseases and diabetes.
  • [MeSH-major] African Americans. Carcinoma, Hepatocellular / ethnology. Carcinoma, Hepatocellular / etiology. European Continental Ancestry Group. Liver Neoplasms / ethnology. Liver Neoplasms / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527700.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Ribatti D, Belloni AS, Nico B, Di Comite M, Crivellato E, Vacca A: Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. Peptides; 2008 Sep;29(9):1596-602
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma.
  • In this study, we have correlated microvascular density and leptin/leptin receptor (Ob-R) expression in endothelial and tumor cells with the histopathological type in human hepatocellular carcinoma (HCC).
  • For this purpose, specimens of 40 primary HCC were submitted to immunohistochemical investigation using anti-CD31, anti-leptin and anti-Ob-R antibodies.
  • [MeSH-major] Carcinoma, Hepatocellular / physiopathology. Leptin / biosynthesis. Liver Neoplasms / physiopathology. Neovascularization, Pathologic / physiopathology. Receptors, Leptin / biosynthesis
  • [MeSH-minor] Adult. Aged. Animals. Chick Embryo. Chorioallantoic Membrane / pathology. Female. Gene Expression. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573568.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Leptin
  •  go-up   go-down


43. Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, Choi JS, Han KH, Chung KY: Surgical resection for pulmonary metastasis from hepatocellular carcinoma: analysis of prognosis in relation to primary control. J Surg Oncol; 2010 Mar 1;101(3):239-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection for pulmonary metastasis from hepatocellular carcinoma: analysis of prognosis in relation to primary control.
  • BACKGROUND: Advances in local treatments for hepatocellular carcinoma (HCC) have seen better prognosis.
  • The median survival time after pulmonary resection was significantly better for HCC controlled by surgery, disease-free time >or=12 months, TMN stage I-II, and T factor 1-2 of primary HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20127898.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Bacaksiz A, Sahin FI, Bilezikci B, Yilmaz Z: Determination of HER-2/Neu status in hepatocellular carcinoma cases. Genet Test; 2008 Jun;12(2):211-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of HER-2/Neu status in hepatocellular carcinoma cases.
  • Specific chromosome abnormalities and genetic changes in hepatocellular carcinoma (HCC) have been demonstrated by conventional cytogenetic studies or molecular cytogenetic approaches like comparative genomic hybridization and loss of heterozygosity analyses.
  • We conclude that although HER-2/Neu amplification is not the primary mechanism in the development of liver tumors, it might play a role in one of the steps of multistage carcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular. Genes, erbB-2. Liver Neoplasms. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Chromosomes, Human, Pair 17 / genetics. DNA, Neoplasm / analysis. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452393.001).
  • [ISSN] 1090-6576
  • [Journal-full-title] Genetic testing
  • [ISO-abbreviation] Genet. Test.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


45. Kothary N, Weintraub JL, Susman J, Rundback JH: Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol; 2007 Dec;18(12):1517-26; quiz 1527
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk.
  • PURPOSE: Transarterial chemoembolization (TACE) has become a standard treatment option for patients with unresectable hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy. Portal Vein / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bilirubin / blood. Female. Humans. Liver Transplantation / statistics & numerical data. Male. Middle Aged. Retrospective Studies. Risk Factors. Serum Albumin / metabolism. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057286.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serum Albumin; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


46. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW: Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology; 2008 Mar;47(3):897-907
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of metastasis-related microRNAs in hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is an aggressive cancer with a dismal outcome largely due to metastasis and postsurgical recurrence.
  • Using a supervised algorithm and a clinically well-defined cohort of 131 cases, we built a unique 20-miRNA metastasis signature that could significantly predict (P < 0.001) primary HCC tissues with venous metastases from metastasis-free solitary tumors with 10-fold cross-validation.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / secondary. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. MicroRNAs / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176954.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


47. Yang W, Chen MH, Yan K, Gao W, Yin SS, Wang YB, Zhang XP, Xing BC, Huang XF: [Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy]. Zhonghua Wai Ke Za Zhi; 2005 Aug 1;43(15):980-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy].
  • OBJECTIVE: To assess the efficiency and safety of radiofrequency ablation (RFA) of recurrent hepatocellular carcinoma (RHCC) after hepatectomy and to investigate efficacy of RFA for patients with early and late phase recurrence, separately, setting 1 year as the cut-off between the early and late phases.
  • METHODS: A total of 42 patients with 77 RHCC and a history of hepatic resection for hepatocellular carcinoma (HCC) underwent ultrasound-guided percutaneous radiofrequency ablation in our department and entered this study (RHCC group).
  • During the same period 148 patients with 217 primary HCC were also treated by RF ablation and regarded as primary HCC group.
  • The average diameter of primary HCC was (4.0 +/- 1.4) cm (range, 1.2-7.0 cm).
  • RESULTS: The ablation success rate, local recurrence rate, new tumor incidence and mean survival in RHCC group were 90.5%, 14.3%, 38.1% and (28.0 +/- 3.5) months, respectively, which were similar to the corresponding results of 87.2%, 16.2%, 37.8% and (39.0 +/- 2.1) month in primary HCC group.
  • However, when further comparison was performed between early recurrence group, late recurrence group and primary HCC group, there were some significant differences.
  • The incidence of new tumors in early recurrence group was significantly higher than that in late recurrent group (60.0% vs. 18.2%, P = 0.005); early recurrence group survived shorter than primary HCC group [(15.4 +/- 2.3) vs. (39.0 +/- 2.1) months, P < 0.005].
  • The survival time was similar between late recurrence group and primary HCC group.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194353.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


48. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer; 2005 Mar 15;103(6):1201-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.
  • BACKGROUND: Radiofrequency ablation (RFA) was introduced recently as a therapeutic modality for hepatocellular carcinoma (HCC), an alternative to percutaneous ethanol injection therapy (PEIT), which is coming into use worldwide.
  • Cumulative survival was also assessed in 319 patients who received RFA as primary treatment (naive patients) and 345 patients who received RFA for recurrent tumor after previous treatment including resection, PEIT, microwave coagulation therapy, and transarterial embolization (nonnaive patients).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / mortality. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / epidemiology. Prevalence. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sex Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690326.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Kawamura Y, Ikeda K, Kumada H: [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin]. Gan To Kagaku Ryoho; 2010 Mar;37(3):402-7
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin].
  • Transcatheter arterial chemoembolization (TACE) has been reported to be an effective palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), and many chemotherapeutic agents such as epirubicin and mitomycin C were used with lipiodol in Japan.
  • A number of molecular-based chemotherapeutic agents are expected to become available in the future, and the primary therapy of advanced stage HCC may change with the introduction of these drugs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Platinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Chemoembolization, Therapeutic. Drug Resistance, Neoplasm. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332675.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Platinum Compounds; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


50. Dong BW, Wen CY, Liang P, Yu XL, Su L, Yu DJ, Xia HT: [Influence of microwave ablation and surgical resection of small primary hepatocellular carcinoma on hematogenous dissemination of tumor cells]. Zhonghua Zhong Liu Za Zhi; 2006 Jan;28(1):39-42
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of microwave ablation and surgical resection of small primary hepatocellular carcinoma on hematogenous dissemination of tumor cells].
  • OBJECTIVE: To study the influence of percutaneous microwave ablation (PMA) and surgical resection for patients with small primary hepatocellular carcinoma (PHC) on dissemination of tumor cells in peripheral blood determined by AFP mRNA.
  • AFP mRNA copies in blood could be detected persistently in the 4 patients with extrahepatic metastasis or liver recurrence.
  • The impairment of liver function is less severe after PMA treatment than surgical resection.
  • PMA may provide certain value for clinical management of small hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation / methods. Liver Neoplasms / therapy. Microwaves / therapeutic use. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Antigens, CD3 / blood. Antigens, CD4 / blood. Antigens, CD8 / blood. CD4-CD8 Ratio. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737619.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / RNA, Messenger; 0 / alpha-Fetoproteins
  •  go-up   go-down


51. Li YL, Ma HB, Guo JX, Shi JB, Xu J, Liu AX, Yang LH, Li BA, Mao YL: [The studies on early warning of Lens culinaris-reactive alpha-Fetoprotein (AFP-L3) detecting in primary hepatocellular carcinoma]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Oct;22(5):336-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The studies on early warning of Lens culinaris-reactive alpha-Fetoprotein (AFP-L3) detecting in primary hepatocellular carcinoma].
  • OBJECTIVE: To explore the significance of Lens culinaris-reactive alpha-Fetoprotein (AFP-L3) detection in primary hepatocellular carcinoma.
  • METHODS: AFP-L3 was isolated by using microspin column coupled with lens culinaris agglutinin (LCA), AFP and AFP-L3 were detected with chemiluminescent immunoassay, the proportion of AFP L3 levels were calculated, and the relationship between the elevated AFP-L3 (%) levels and benign and malignant liver disease was analyzed.
  • RESULTS: There were significant differences in positive rate between the patients of HCC, suspected HCC and other liver disease (81.80%, 73.68%, 11.80%, respectively, P < 0.05).
  • Among the undetermined HCC (suspected HCC, liver disease) patients, 12 out of 21 cases of AFP-13 positive were diagnosed to be HCC within 6 months, and 6 of them were diagnosed to be the single small HCC at the early stage through B-Ultrasonic Diagnosis or CT.
  • The detection of AFP-L3 has a significant implication for the identification of benign or malignant liver disease and the early stage predictive diagnosis of HCC while AFP increases.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / diagnosis. Lens Plant / chemistry. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Plant Lectins / analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469167.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Plant Lectins; 0 / alpha-Fetoproteins; 0 / lentil lectin
  •  go-up   go-down


52. Ochiai T, Sonoyama T, Kikuchi S, Konishi H, Kitagawa M, Okayama T, Ichikawa D, Ueda Y, Otsuji E, Yamagishi H: Results of repeated hepatectomy for recurrent hepatocellular carcinoma. Hepatogastroenterology; 2007 Apr-May;54(75):858-61
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of repeated hepatectomy for recurrent hepatocellular carcinoma.
  • BACKGROUND/AIMS: The long-term outcome of patients undergoing repeated hepatectomy for secondary hepatocellular carcinoma (HCC) were investigated to assess the selection criteria for, and efficacy of, repeated hepatectomy.
  • Clinical characteristics, histopathologic findings and postoperative clinical course were compared for patients with primary and secondary HCCs in the R group.
  • RESULTS: There were no significant differences in patient characteristics or histologic features of primary and secondary HCCs in the R group.
  • A significant difference in cumulative postoperative disease-free survival was not seen for primary and secondary HCCs, average duration was 39.4 and 21.3 months.
  • Liver cirrhosis and narrow hepatectomy (subsegmentectomy, limited resection and enucleation) were found to be significant risk factors of survival after secondary hepatectomy.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatectomy. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591079.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


53. Wang BW, Mok KT, Liu SI, Chou NH, Tsai CC, Chen IS, Yeh MH, Chen YC: Is hepatectomy beneficial in the treatment of multinodular hepatocellular carcinoma? J Formos Med Assoc; 2008 Aug;107(8):616-26
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is hepatectomy beneficial in the treatment of multinodular hepatocellular carcinoma?
  • BACKGROUND/PURPOSE: Hepatectomy remains the standard treatment for primary hepatocellular carcinoma (HCC).
  • Hepatectomy is the treatment of choice if the tumors can be removed by one-block resection and liver function reserve is acceptable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Formos Med Assoc. 2008 Dec;107(12):971; author reply 972 [19129060.001]
  • (PMID = 18678545.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


54. Gao YW, Chen YX, Wang ZM, Zhou LD, Li XY, Li LX, Luo QZ, Tian W, Fu CY, Zhou JH: Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):345-50
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
  • BACKGROUND/AIMS: Recent studies have found that Cyclooxygenase-2(Cox-2) is frequently inappropriately expressed in primary hepatocellular carcinoma (HCC), suggesting that abnormal Cox-2 expression plays an important role in hepatocarcinogenesis.
  • Normal liver tissues of 10 hemangiomas were collected as controls.
  • RESULTS: In 25 HCC patients, remarkably higher Cox-2 expression in both tumor and ANT tissues was observed compared with normal liver tissues (p < 0.001).
  • [MeSH-major] Antigens, CD4. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cyclooxygenase 2 / biosynthesis. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613363.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD4; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


55. Yan K, Chen MH, Yang W, Wang YB, Gao W, Hao CY, Xing BC, Huang XF: Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol; 2008 Aug;67(2):336-47
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors.
  • PURPOSE: To investigate the efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), and the prognostic factors for post-RFA survival rate.
  • Nine potential factors were found with significant effects on survival rate, and they were number of tumors, location of tumors, pre-RFA liver function enzymes, Child-Pugh classification, AJCC staging, primary or recurrent HCC, tumor pathological grading, using mathematical protocol in RFA procedure and tumor necrosis 1 month after RFA.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765421.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


56. Peng BG, Liang LJ, He Q, Kuang M, Lia JM, Lu MD, Huang JF: Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol; 2005 Feb 7;11(5):700-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor vaccine against recurrence of hepatocellular carcinoma.
  • AIM: To investigate the effects of autologous tumor vaccine on recurrence of hepatocellular carcinoma (HCC).
  • Primary endpoints were the time of recurrence.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Antigen-Presenting Cells. Antigens, Neoplasm. Disease-Free Survival. Female. Humans. Hypersensitivity, Delayed / etiology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655825.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  • [Other-IDs] NLM/ PMC4250742
  •  go-up   go-down


57. Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, Li H, Hao X: Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg; 2008 Sep;12(9):1540-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma.
  • AIMS: To clarify the incidence of multicentric occurrence (MO) and intrahepatic metastasis (IM) for hepatocellular carcinoma (HCC) related to hepatitis B virus in China and to identify the differences between them.
  • METHODS: Histopathologic and genetic features of primary and recurrent tumors in 160 cases with HCC were analyzed.
  • By comparing the genetic information of loss of heterozygosity and microsatellite instability for 10 different markers between primary and recurrent tumor, 30.0% and 63.8% patients with recurrent HCC were considered to be MO and IM, respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Hepatitis B / epidemiology. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Age Distribution. Biopsy, Needle. China / epidemiology. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Multivariate Analysis. Neoplasm Staging. Polymerase Chain Reaction. Probability. Regression Analysis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18629593.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Xian ZH, Zhang SH, Cong WM, Wu WQ, Wu MC: Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J Clin Pathol; 2005 May;58(5):500-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most prevalent fatal cancers in the world.
  • METHODS: Eight hundred and sixty eight surgical samples from patients with primary HCC were examined for their HER-2/neu status.
  • RESULTS: HER-2/neu overexpression was detected in 21 (2.42%) of the 868 primary HCCs.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Amplification. Genes, erbB-2 / genetics. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Anticarcinogenic Agents / therapeutic use. Biomarkers, Tumor / analysis. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence / methods. Male. Middle Aged. Trastuzumab

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jul;17(7):1983-7 [10561248.001]
  • [Cites] Diagn Mol Pathol. 2004 Dec;13(4):213-6 [15538111.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1377-83 [11355950.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3239-50 [11595720.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):415-20 [11900227.001]
  • [Cites] World J Gastroenterol. 2002 Jun;8(3):385-92 [12046056.001]
  • [Cites] Am J Clin Pathol. 2002 Sep;118(3):408-17 [12219783.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Sep;10(3):237-41 [12373150.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3626-31 [12839951.001]
  • [Cites] Oncologist. 2003;8(4):307-25 [12897328.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6570-8 [14528282.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2110-5 [14647146.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):143-6 [14991529.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):233-7 [14990588.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):241-2 [14990591.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1706-16 [15014023.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2512-24 [15073131.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3981-6 [15173011.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1140-4 [15509672.001]
  • [Cites] J Hepatol. 1992 Mar;14(2-3):377-80 [1380026.001]
  • [Cites] Oncogene. 1994 Jul;9(7):1829-38 [7911565.001]
  • [Cites] Histol Histopathol. 1994 Oct;9(4):677-82 [7894139.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2825-31 [9661897.001]
  • [Cites] Digestion. 1998 Aug;59(5):556-62 [9705539.001]
  • [Cites] Clin Ther. 1999 Feb;21(2):309-18 [10211534.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4A):2501-3 [10470182.001]
  • [Cites] J Clin Pathol. 2000 May;53(5):374-81 [10889820.001]
  • (PMID = 15858121.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Anticarcinogenic Agents; 0 / Biomarkers, Tumor; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ PMC1770655
  •  go-up   go-down


59. Sloane D, Chen H, Howell C: Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc; 2006 Dec;98(12):1934-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival.
  • OBJECTIVES: The incidence and mortality rates from primary hepatocellular carcinoma (HCC) are higher in black Americans compared to whites.

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):2060-3 [14499788.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):355-60 [16527700.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):601-9 [15280639.001]
  • [Cites] Cancer Pract. 1998 May-Jun;6(3):182-7 [9652250.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):413-8 [16365180.001]
  • [Cites] Liver Transpl. 2004 Jul;10(7):834-41 [15237365.001]
  • (PMID = 17225837.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 1 K24 DK072036-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569668
  •  go-up   go-down


60. Ikeda S: [Adult-onset citrullinemia]. Brain Nerve; 2007 Jan;59(1):59-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult-onset citrullinemia].
  • Adult-onset citrullinemia (CTLN2) is a rare hereditary metabolic disorder characterized by highly increased concentration of citrulline and ammonia in the plasma, which is ascribed to a deficiency of argininosuccinate synthetase (ASS), one of the urea cycle enzymes mainly located in the liver.
  • However, in 1995 the first CTLN2 patient who was successfully treated by living-related liver transplantation was reported and since then more than 30 patients had underwent this operation in our country, showing good outcomes.
  • No primary defect had not been found within ASS gene locus, but the causative gene of this disorder is now identified as the "citrin gene", which might act as a aspartate/glutamate transporter in mitochondria.
  • Different phenotypes are seen in the individuals with a citrin deficiency: neonatal intrahepatic cholestasis, juvenile-onset chronic pancreatitis and hepatocellular carcinoma without cirrhosis can precede the appearance of CTLN2.
  • [MeSH-minor] Administration, Oral. Adult. Age of Onset. Arginine / administration & dosage. Argininosuccinate Synthase. Calcium-Binding Proteins / genetics. Cholestasis, Intrahepatic / etiology. Chronic Disease. Glycerol / contraindications. Humans. Liver Neoplasms / etiology. Liver Transplantation. Mutation. Organic Anion Transporters / genetics. Pancreatitis / etiology. Phenotype

  • Genetic Alliance. consumer health - Citrullinemia.
  • Hazardous Substances Data Bank. GLYCERIN .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354380.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Organic Anion Transporters; 1340-08-5 / citrin; 94ZLA3W45F / Arginine; EC 6.3.4.5 / Argininosuccinate Synthase; PDC6A3C0OX / Glycerol
  • [Number-of-references] 34
  •  go-up   go-down


61. Ikeda S: [Adult-onset citrullinemia]. No To Shinkei; 2007 Jan;59(1):59-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult-onset citrullinemia].
  • Adult-onset citrullinemia (CTLN2) is a rare hereditary metabolic disorder characterized by highly increased concentration of citrulline and ammonia in the plasma, which is ascribed to a deficiency of argininosuccinate synthetase (ASS), one of the urea cycle enzymes mainly located in the liver.
  • However, in 1995 the first CTLN2 patient who was successfully treated by living-related liver transplantation was reported and since then more than 30 patients had underwent this operation in our country, showing good outcomes.
  • No primary defect had not been found within ASS gene locus, but the causative gene of this disorder is now identified as the "citrin gene", which might act as a aspartate/glutamate transporter in mitochondria.
  • Different phenotypes are seen in the individuals with a citrin deficiency: neonatal intrahepatic cholestasis, juvenile-onset chronic pancreatitis and hepatocellular carcinoma without cirrhosis can precede the appearance of CTLN2.
  • [MeSH-minor] Administration, Oral. Age of Onset. Arginine / administration & dosage. Argininosuccinate Synthase. Calcium-Binding Proteins / genetics. Cholestasis, Intrahepatic / etiology. Chronic Disease. Glycerol / contraindications. Liver Neoplasms / etiology. Liver Transplantation. Mutation. Organic Anion Transporters / genetics. Pancreatitis / etiology. Phenotype

  • Hazardous Substances Data Bank. GLYCERIN .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228780.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Organic Anion Transporters; 1340-08-5 / citrin; 94ZLA3W45F / Arginine; EC 6.3.4.5 / Argininosuccinate Synthase; PDC6A3C0OX / Glycerol
  • [Number-of-references] 34
  •  go-up   go-down


62. Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A: Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer; 2007 Nov 5;97(9):1260-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma.
  • Hepatocellular carcinoma (HCC) is highly malignant and prone to multicentric occurrence.
  • Differentiation between a true relapse of HCC and a second primary tumour appearing is of clinical importance.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. DNA Methylation. DNA, Neoplasm / genetics. Genes, Tumor Suppressor. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5 [9618505.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):71-3 [9892188.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Hepatology. 1999 May;29(5):1446-52 [10216128.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4347-53 [10361133.001]
  • [Cites] Liver Int. 2005 Apr;25(2):380-8 [15780064.001]
  • [Cites] Hepatology. 2000 Mar;31(3):615-21 [10706551.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):431-40 [10930378.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4366-71 [10969779.001]
  • [Cites] Nat Genet. 2001 May;28(1):29-35 [11326271.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8094-9 [11719434.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):481-7 [11839667.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1087-92 [11948118.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2593-604 [11971194.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5295-8 [14614012.001]
  • [Cites] Biochem Biophys Res Commun. 1985 Jul 16;130(1):118-26 [2992457.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3674-8 [1319827.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4 [7937876.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11733-7 [7972132.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):67-70 [9892187.001]
  • (PMID = 17968429.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2360457
  •  go-up   go-down


63. Choi JI, Choi HJ, Jung DC, Kim MJ, Hong EK, Park JW, Jang YJ, Kim CM: Diagnostic value of early-phase-enhanced computed tomography for the differentiation of pulmonary metastases from hepatocellular carcinoma and primary lung cancer. Acta Radiol; 2009 Nov;50(9):1005-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of early-phase-enhanced computed tomography for the differentiation of pulmonary metastases from hepatocellular carcinoma and primary lung cancer.
  • BACKGROUND: The lung is the most common site of distant metastases from hepatocellular carcinoma.
  • Correct differentiation between metastatic hepatocellular carcinoma of the lung and primary lung cancer is sometimes difficult without biopsy.
  • PURPOSE: To evaluate the usefulness of measuring the attenuations of pulmonary nodules on early-phase contrast-enhanced computed tomography (CT) for the differentiation of pulmonary metastases from hepatocellular carcinoma and primary lung cancer.
  • MATERIAL AND METHODS: Thirteen patients with pulmonary metastases from hepatocellular carcinoma (nine men, four women; age 53.9+/-14.2 years, range 16-70 years) and 25 patients with primary lung cancer (14 men, 11 women; age 62.2+/-9.4 years, range 43-72 years) were retrospectively evaluated.
  • RESULTS: The mean attenuation value of metastatic pulmonary nodules from hepatocellular carcinoma (75.7+/-24.9 HU) was higher than that of primary lung cancer nodules (45.8+/-14.4 HU) (P<0.01).
  • When a cut-off value of 75 HU was applied, the positive predictive value for diagnosing metastatic nodules from hepatocellular carcinoma was 100%.
  • CONCLUSION: Pending confirmation in a large study, our findings suggest that there is a difference in contrast enhancement between pulmonary metastases from hepatocellular carcinoma and primary lung cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Contrast Media. Diagnosis, Differential. Female. Humans. Iohexol / analogs & derivatives. Linear Models. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863410.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


64. Kwon JB, Park K, Kim YD, Seo JH, Moon SW, Cho DG, Kim YW, Kim DG, Yoon SK, Lim HW: Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors. World J Gastroenterol; 2008 Oct 7;14(37):5717-22
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors.
  • At the end of the follow-up, 1 patient died from hepatic failure without recurrence, 6 died from hepatic failure with a recurrent hepatocellular carcinoma (HCC), and 4 died from recurrent HCC with cachexia.
  • Among several clinical factors, Kaplan-Meier analysis revealed that liver transplantation as a treatment for the primary lesion, grade of cell differentiation, and negative evidence HBV infection were independent predictive factors.
  • Although not significant, patients with liver transplantation of a primary HCC survived longer.
  • Liver transplantation might be the most beneficial modality that can offer patients better survival.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / therapy. Lung Neoplasms / surgery. Pulmonary Surgical Procedures
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cell Differentiation. Female. Hepatectomy. Hepatitis B / complications. Humans. Kaplan-Meier Estimate. Liver Transplantation / adverse effects. Male. Middle Aged. Patient Selection. Proportional Hazards Models. Risk Assessment. Risk Factors. Thoracoscopy. Thoracotomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):251-7 [9058154.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):720-6 [8780578.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1198-200 [9752858.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Nov;54(5):415-20 [15235823.001]
  • [Cites] J Chin Med Assoc. 2004 Dec;67(12):621-4 [15779485.001]
  • [Cites] World J Surg. 2005 Jun;29(6):715-8 [16078127.001]
  • [Cites] J Hepatol. 2005 Oct;43(4):584-9 [16120468.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7 [16246200.001]
  • [Cites] Am J Surg. 2006 Jul;192(1):46-51 [16769274.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):152-6 [17419251.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Jul 1;26(1):87-94 [17555425.001]
  • [Cites] J Thorac Cardiovasc Surg. 1965 Mar;49:357-63 [14265951.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1815-20 [10585064.001]
  • [Cites] Radiology. 2000 Sep;216(3):698-703 [10966697.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1088-93 [11490807.001]
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):311-8 [12229937.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1688-9 [15162554.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):825-9 [15143926.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(3):386-8 [12353153.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1428-33 [15362769.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1123-39, ix [15488562.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):401-5 [6198058.001]
  • [Cites] Semin Surg Oncol. 1990;6(5):297-302 [2237090.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):316-9 [7691699.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):86-92 [9683759.001]
  • (PMID = 18837090.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2748208
  •  go-up   go-down


65. Kuiper EM, Hansen BE, Adang RP, van Nieuwkerk CM, Timmer R, Drenth JP, Spoelstra P, Brouwer HT, Kuyvenhoven JP, van Buuren HR, Dutch PBC Study Group: Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol; 2010 Dec;22(12):1495-502
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid.
  • BACKGROUND: The reported incidence of hepatocellular carcinoma (HCC) among patients with primary biliary cirrhosis (PBC) varies from 0.7-3.8%, whereas in cirrhotic patients the risk is considerably higher.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Cholagogues and Choleretics / therapeutic use. Liver Cirrhosis, Biliary / drug therapy. Liver Neoplasms / etiology. Ursodeoxycholic Acid / therapeutic use
  • [MeSH-minor] Adult. Aged. Cause of Death. Female. Humans. Incidence. Kaplan-Meier Estimate. Male. Mass Screening. Middle Aged. Netherlands / epidemiology. Patient Selection. Proportional Hazards Models. Prospective Studies. Risk Assessment. Risk Factors. Survival Rate. Time Factors. Treatment Failure

  • Genetic Alliance. consumer health - Primary biliary cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21389798.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  • [Investigator] Wagtmans MJ; Robijn RJ; de Vries RA; Leeuwerik PJ; Rasica M; Lückers AE; Rijk MC; Ras GJ; van Deursen CT; van der Hoek EW; de Bruijne JW; van Munster IP; van Ditzhuijzen TJ; Houben MH; Valentijn RM; van der Werf SD; ter Borg F; Beukers R; Lesterhuis W; van Vliet AC; Ponssen HH; Eichhorn RF; van de Vrie W; Witteman BJ; van Aken J; Stronkhorst A; Boekema PJ; Kerbert-Dreteler MJ; de Kan R; Haagsma E; Groen JN; Tan TG; van Berkum FN; Thijs JC; Zwertbroek R; Grool TA; van Hoek B; Koek GH; van Hees PN; de Koning RW; de Sévaux RG; de Boer WA; Biemond P; van Tilburg AJ; den Ouden JW; Kubben FJ; Zeijen RN; Engels LG; Looij BJ; Wolfhagen FH; van Erpecum KJ; Vleggaar FP; Tanis AA; Breed JG; Loffeld BC; van Dobbenburgh OA; Lambert J
  •  go-up   go-down


66. Malik SM, Gupte PA, de Vera ME, Ahmad J: Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol; 2009 Jul;7(7):800-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma.
  • BACKGROUND & AIMS: The increasing incidence of hepatocellular carcinoma in the United States is only partially accounted for by hepatitis C virus (HCV) infections.
  • The prevalence of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis (NASH) is not known; guidelines from the American Association for the Study of Liver Diseases do not recommend surveillance imaging.
  • We sought to determine the prevalence of hepatocellular carcinoma among patients undergoing liver transplantation for NASH-related cirrhosis and their outcome after surgery, compared with controls.
  • METHODS: We reviewed the records of adult patients with NASH cirrhosis who underwent liver transplantation by using a prospectively collected database from a single center.
  • Data from patients with NASH cirrhosis were compared with matched controls who received transplantation for primary biliary cirrhosis/primary sclerosing cholangitis, alcoholic liver disease, or HCV.
  • RESULTS: Seventeen of 98 patients (17%) with NASH cirrhosis were diagnosed with hepatocellular carcinoma.
  • Six patients were diagnosed with hepatocellular carcinoma incidentally on explant.
  • Survival after liver transplantation was 88% after mean follow-up of 2.5 years.
  • The number of NASH patients known to have hepatocellular carcinoma before liver transplantation was greater than the number of patients with primary biliary cirrhosis/primary sclerosing cholangitis and comparable to the number of patients with alcoholic liver disease and HCV.
  • CONCLUSIONS: Patients with NASH cirrhosis are at risk for developing hepatocellular carcinoma; patients with NASH cirrhosis, especially men older than 50 years, should undergo surveillance imaging.
  • Patients with NASH and hepatocellular carcinoma have good outcomes after liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / surgery. Fatty Liver / complications. Fatty Liver / epidemiology. Liver Transplantation
  • [MeSH-minor] Adult. Age Factors. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Risk Factors. Sex Factors. Survival Analysis. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2009 Oct;15(10):1367-8 [19806686.001]
  • (PMID = 19281869.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Cai XJ, Xu GG, Shen B: [Expression of RhoC protein in human primary hepatocellular carcinoma and its clinical significance]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2006 Jul;35(4):394-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of RhoC protein in human primary hepatocellular carcinoma and its clinical significance].
  • OBJECTIVE: To detect the expression of RhoC protein in human primary hepatocellular carcinoma (HCC) and pericancerous liver (PCL) tissues and its relation to HCC prognosis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. rho GTP-Binding Proteins / biosynthesis
  • [MeSH-minor] Adult. Female. Humans. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924703.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RHOC protein, human; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


68. Zhou L, Yang YP, Feng YY, Lu YY, Wang CP, Wang XZ, An LJ, Zhang X, Wang FS: Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study. Ai Zheng; 2009 Jan;28(1):45-8
Hazardous Substances Data Bank. HELIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of argon-helium cryosurgical ablation on primary hepatocellular carcinoma: a pilot clinical study.
  • BACKGROUND AND OBJECTIVE: Recent years, great progression has been made in treating primary hepatocellular carcinoma (HCC) with argon-helium cryosurgical ablation.
  • This study was to evaluate its efficacy on unresectable primary HCC.
  • METHODS: A total of 124 primary HCC patients were divided into early stage, middle stage and advanced stage groups according to BCLC staging classification.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Cryosurgery / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Argon. Female. Helium. Humans. Liver / physiopathology. Male. Middle Aged. Pilot Projects. Postoperative Complications / epidemiology. Survival Rate. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Argon, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448416.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 206GF3GB41 / Helium; 67XQY1V3KH / Argon
  •  go-up   go-down


69. Fernández-Ruiz M, Guerra-Vales JM, Castelbón-Fernández FJ, Llenas-García J, Caurcel-Díaz L, Colina-Ruizdelgado F: Multiple primary malignancies in Spanish patients with hepatocellular carcinoma: analysis of a hospital-based tumor registry. J Gastroenterol Hepatol; 2009 Aug;24(8):1424-30
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple primary malignancies in Spanish patients with hepatocellular carcinoma: analysis of a hospital-based tumor registry.
  • BACKGROUND AND AIM: Little is known about the etiological associations and clinical features of extrahepatic primary malignant (EHPM) neoplasms in subjects with hepatocellular carcinoma (HCC).
  • Subjects identified with a second primary malignancy elsewhere constituted the EHPM group and were compared to patients with HCC alone.
  • The associated cancers included five cases of colorectal carcinoma, four cases of head and neck carcinoma, three cases of genitourinary cancer, two cases of lymphoproliferative disorder, one lung carcinoma, one skin melanoma, one breast carcinoma, and two cancers of unknown origin.
  • Age and sex distribution, etiology of underlying hepatopathy, and liver function tests did not differ significantly between both groups.
  • Our results suggest that the association of another primary tumor with HCC does not imply a worse prognosis.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology. Neoplasms, Multiple Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Hospitals / statistics & numerical data. Humans. Kaplan-Meier Estimate. Middle Aged. Registries. Retrospective Studies. Spain / epidemiology. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486257.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


70. Wang J, Qin Y, Li B, Sun Z, Yang B: Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem; 2006 Apr;39(4):344-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients.
  • To explore the aberrant promoter CpG island methylation of the GSTP1 gene as a biomarker for screening hepatocellular carcinoma (HCC) high risk individuals and for the early detection of HCC, we analyzed its methylation in the tumor and non-tumor tissues and serum samples from 26 patients with HCC, as well as serum from 8 liver cirrhosis patients by methylation-specific PCR (MSP).
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. DNA Methylation. Glutathione S-Transferase pi / genetics. Liver Neoplasms / enzymology. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527261.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


71. Zhang FJ, Li CX, Jiao DC, Zhang NH, Wu PH, Duan GF, Wu YX: CT guided 125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma. Chin Med J (Engl); 2008 Dec 5;121(23):2410-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT guided 125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma.
  • BACKGROUND: This study evaluated the clinical application of CT guided 125iodine implantation in patients with portal vein tumor thrombus in primary hepatocellular carcinoma.
  • METHODS: The ten patients (9 males and 1 female, aged from 36 to 72 years) with portal vein tumor thrombus accompanying hepatocellular carcinoma had been treated with comprehensive therapy including surgery, transcatheter arterial chemoembolization, radiotherapy ablation, microwave ablation or percutaneous ethanol injection.
  • CONCLUSION: CT guided implantation of 125iodine seeds, can effectively treat portal vein tumor thrombus accompanying hepatocellular carcinoma with minimal damage and few complications.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Iodine Radioisotopes / therapeutic use. Liver Neoplasms / radiotherapy. Portal Vein. Venous Thrombosis / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy / methods. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102958.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


72. Nan KJ, Ruan ZP, Jing Z, Qin HX, Wang HY, Guo H, Xu R: Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis. World J Gastroenterol; 2005 Jan 14;11(2):228-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.
  • AIM: To evaluate the expression of fragile histidine triad (FHIT) gene protein, product of a candidate tumor suppressor, and to investigate the relationship between FHIT, cell apoptosis and proliferation, and pathological features of primary hepatocellular carcinoma (HCC).
  • METHODS: Forty-seven HCC and ten normal liver specimens were collected during surgical operation between 2001 and 2003.
  • FHIT and proliferating cell nuclear antigen (PCNA) expression were detected by immunohistochemistry, and apoptotic level was evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay on the tissue sections.
  • RESULTS: All normal liver tissues showed a strong expression of FHIT, whereas 28 of 47 (59.6%) carcinomas showed a significant loss or absence of FHIT expression (P = 0.001).
  • Apoptotic incidence in advanced TNM stage carcinoma and those with positive FHIT expression was higher than that in early stage carcinoma (P = 0.030) and in those with negative FHIT expression (P = 0.044) respectively.
  • The proliferating potential of hepatocellular carcinoma was associated with FHIT expression (P = 0.016) and the aggressive feature (P = 0.019).
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Apoptosis / genetics. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cell Division / genetics. Genes, Tumor Suppressor. Histidine / genetics. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Female. Humans. Liver / physiology. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Reference Values

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15633221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 4QD397987E / Histidine; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4205407
  •  go-up   go-down


73. Zhang Q, Zhang XL, Zhang YZ, Cheng GX, Chen ZQ: [Hemodynamic study of primary hepatocellular carcinoma evolved from viral-induced cirrhosis using CT perfusion imaging]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Nov;28(11):1986-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemodynamic study of primary hepatocellular carcinoma evolved from viral-induced cirrhosis using CT perfusion imaging].
  • OBJECTIVE: To investigate the hemodynamic changes of primary hepatocellular carcinoma (HCC) evolved from hepatic cirrhosis using CT perfusion imaging.
  • METHODS: Thirty-two patients with primary hepatocellular carcinoma evolved from virus-induced fibrosis or cirrhosis underwent dynamic CT scanning of the target slices for 60 min.
  • Paired-sample t test was used to determine the differences in the perfusion parameters between the hepatic parenchyma and the primary HCC mass.
  • RESULTS: Compared with hepatic BF (117.13-/+31.05 ml/100 mg/min), BV (14.73-/+3.91 ml/100 mg), PS (31.93-/+5.91 ml/100 mg/min), HAF (25.02-/+8.19%), MTT (12.79-/+3.31 s), IRF TO (3.14-/+1.09 s), the primary HCC mass showed significant increments in the BF (239.69-/+96.07 ml/100 mg/min), BV (20.26-/+6.73 ml/100 mg), PS (37.50-/+9.50 ml/100 mg/min), HAF (68.97-/+15.22%) with decreased MTT (7.17-/+1.38 s) and IRF TO (2.42-/+0.94 s).
  • CONCLUSION: Liver perfusion parameters can represent the hemodynamic changes in the HCC derived from hepatic cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / physiopathology. Hemodynamics. Liver Neoplasms / physiopathology. Perfusion / methods. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Female. Hepatitis / complications. Humans. Image Interpretation, Computer-Assisted / methods. Liver Cirrhosis / complications. Male. Middle Aged. Radiographic Image Enhancement / instrumentation. Radiographic Image Enhancement / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033109.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


74. Wakasa T, Wakasa K, Shutou T, Hai S, Kubo S, Hirohashi K, Umeshita K, Monden M: A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma. Hepatogastroenterology; 2007 Mar;54(74):508-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
  • BACKGROUND/AIMS: Combined hepatocellular and cholangiocarcinoma of the liver is relatively infrequent, and its pathogenesis remains obscure.
  • METHODOLOGY: In this study, we investigated the histopathological features, Ki-67 labeling index, and p53 immunohistochemistry of 18 surgically resected cases of combined hepatocellular and cholangiocarcinoma among 1102 consecutive cases of surgically resected primary liver cancers.
  • Microscopically, we classified the cases into the following three categories according to the arrangement of the hepatocellular carcinoma and cholangiocarcinoma components;.
  • (1) Type I in which hepatocellular carcinoma and cholangiocarcinoma formed nodules that could easily be distinguished from each other, (2) Type II in which the both components were finely mixed, so that the two components were almost indistinguishable, and (3) Type III in which the tumors had lobular structures with hepatocellular carcinomas existing centrally and cholangiocarcinomas existing peripherally.
  • In one case of type I, well differentiated hepatocellular carcinoma demonstrated cholangiocarcinoma in "nodules-in-nodules" fashion.
  • The average of Ki-67 labeling index of hepatocellular carcinoma component of combined hepatocellular and cholangiocarcinoma was 4.4 +/- 3.4% and the index of cholangiocarcinoma component was 11.0 +/- 8.5%, which is significantly higher than that of the hepatocellular carcinoma component.
  • In one case, the cholangiocarcinoma component was positive for p53, but the hepatocellular carcinoma component was negative.
  • In the other 4 cases, both the hepatocellular carcinoma and cholangiocarcinoma components were positive.
  • Metaplasia of hepatocellular carcinoma to intrahepatic cholangiocarcinoma is assumed to be one of the pathogenic pathways of combined hepatocellular and cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Aged. Cell Division / physiology. Cell Transformation, Neoplastic / pathology. Female. Hepatitis B, Chronic / pathology. Hepatitis C, Chronic / pathology. Humans. Immunoenzyme Techniques. Ki-67 Antigen / analysis. Liver / pathology. Male. Metaplasia. Middle Aged. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523309.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


75. Lee SG, Hwang S, Jung JP, Lee YJ, Kim KH, Ahn CS: Outcome of patients with huge hepatocellular carcinoma after primary resection and treatment of recurrent lesions. Br J Surg; 2007 Mar;94(3):320-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with huge hepatocellular carcinoma after primary resection and treatment of recurrent lesions.
  • BACKGROUND: Tumour recurrence is common after hepatic resection of hepatocellular carcinomas (HCCs) greater than 10 cm in diameter.
  • This study evaluated the outcome of patients with huge HCC after primary resection and treatment of recurrent lesions.
  • METHODS: A retrospective review was undertaken of clinical data for 100 patients with huge HCC who underwent liver resection.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery. Neoplasm Metastasis / therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 British Journal of Surgery Society Ltd.
  • (PMID = 17205495.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Zhang L, Ren ZG, Gan YH, Wang YH, Zhang BH, Chen Y, Xie XY, Ge NL, Ye SL: [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Aug;32(8):630-3
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC).
  • METHODS: During the period from December 2005 to March 2009, 50 patients with unresectable primary HCC of Child-Pugh status A were treated with sorafenib (400 mg, Bid).
  • The common adverse events were dermal reaction (68.0%, 34/50), diarrhea (52.0%, 26/50), hypertension (4.0%, 2/50), hair loss (14.0%, 7/50), myelosuppression (16.0%, 8/50), and liver dysfunction (20.0%, 10/50).
  • CONCLUSION: Soafenib is effective for unresectable primary HCC with tolerable toxicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Chemoembolization, Therapeutic / methods. Diarrhea / chemically induced. Disease Progression. Follow-Up Studies. Humans. Hypertension / chemically induced. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Skin Diseases / chemically induced. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122420.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


77. Jingting J, Changping W, Ning X, yibei Z, Jun W, Mei J, Bin X, Peter NE, Xueguan Z: Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma. J Clin Lab Anal; 2009;23(4):213-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma.
  • We evaluated clinical significance of serum alpha-fetoprotein (AFP)-IgM immune complexes, in comparison with free AFP, on the diagnosis of primary hepatocellular carcinoma (HCC).
  • Serum levels of AFP-IgM immune complexes and free AFP were determined by the ELISA method and electrochemiluminescence, respectively, in 103 healthy controls, 74 patients suffering from primary HCC, 27 patients suffering from liver cirrhosis, and 63 patients suffering from chronic hepatitis.
  • The best cut-off value of AFP-IgM and free AFP for diagnosis of primary HCC were 300 AU/mL and 10 microg/L respectively, according to the area under the curve (AUC) in this study.
  • The sensitivity of AFP-IgM and free AFP were 64.9 and 79.7%, and the specificity were 75.6 and 80.3%, respectively, when all cases of primary HCC were analyzed, and the AUC of free AFP was larger than that of AFP-IgM (0.85 vs. 0.72, Z=3.21).
  • However, in case of primary HCC at early stages (stages I and II) were analyzed, the AUC of AFP-IgM was larger than that of free AFP (0.91 vs. 0.82, Z=1.73), which demonstrated that the sensitivity of AFP-IgM and free AFP were 94.4 and 72.2%, and the specificity were 81.9 and 79.9%, respectively.
  • When both AFP-IgM and free AFP were positive, the specificity of diagnosis of primary HCC was 89.1%, and the efficacy was 79.0%.
  • It is concluded that either sensitivity or specificity of serum level of AFP-IgM immune complexes was higher than that of free AFP in the diagnosis of primary HCC at early stages.
  • As there was false positive AFP-IgM existed in the patients suffering from cirrhosis and chronic hepatitis, the combination of free AFP and AFP-IgM could significantly increase specificity and decrease false negative and/or false positive in the primary HCC at early stages.
  • [MeSH-major] Antigen-Antibody Complex / blood. Carcinoma, Hepatocellular / diagnosis. Immunoglobulin M / blood. Liver Neoplasms / diagnosis. alpha-Fetoproteins / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Biomarkers, Tumor / blood. Electrochemical Techniques. Enzyme-Linked Immunosorbent Assay. Female. Humans. Luminescence. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623644.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Antigen-Antibody Complex; 0 / Biomarkers, Tumor; 0 / Immunoglobulin M; 0 / alpha-Fetoproteins
  •  go-up   go-down


78. Mu LN, Cao W, Zhang ZF, Cai L, Jiang QW, You NC, Goldstein BY, Wei GR, Chen CW, Lu QY, Zhou XF, Ding BG, Chang J, Yu SZ: Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary hepatocellular carcinoma (HCC) in a Chinese population. Cancer Causes Control; 2007 Aug;18(6):665-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary hepatocellular carcinoma (HCC) in a Chinese population.
  • OBJECTIVES: Methylenetetrahydrofolate reductase (MTHFR), which is expressed in the liver, may be involved in both DNA methylation and DNA synthesis.
  • It is also indicated as a potential risk factor of liver cancer in patients with chronic liver disease.
  • To date, no study has been conducted on MTHFR and hepatocellular carcinoma (HCC) using a population-based design.
  • The objective of this study was to evaluate the effects of polymorphisms of the MTHFR gene on the risk of primary liver cancer and their possible effect modifications on various environmental risk factors.
  • Subjects carrying any T genotype have the increased risk of 1.55(95% CI: 1.01-2.40) for development of primary hepatocellular carcinoma.
  • CONCLUSION: We observed that the MTHFR 677 C/T genotype was associated with an increased risk of primary liver cancer in a Chinese population.
  • The polymorphism of MTHFR 677 might modify the effects of raw water drinking on the risk of primary hepatocellular carcinoma.

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17503006.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA16042; United States / NCCIH NIH HHS / AT / AT00151; United States / NCI NIH HHS / CA / P30 CA042710; United States / NCI NIH HHS / CA / T32 CA009142; United States / NCI NIH HHS / CA / P30 CA016042; United States / NCI NIH HHS / CA / CA77954; United States / NCCIH NIH HHS / AT / P50 AT000151; United States / NCI NIH HHS / CA / CA42710; United States / NCI NIH HHS / CA / R03 CA077954; United States / NIEHS NIH HHS / ES / R21 ES011667; United States / NIEHS NIH HHS / ES / ES011667; United States / NCI NIH HHS / CA / P01 CA042710; United States / NCI NIH HHS / CA / CA09142; United States / NIEHS NIH HHS / ES / ES06718
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  • [Other-IDs] NLM/ NIHMS626432; NLM/ PMC4165489
  •  go-up   go-down


79. Lin JJ, Jin CN, Zheng ML, Ouyang XN, Zeng JX, Dai XH: Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation. Chin J Integr Med; 2005 Jun;11(2):104-10
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation.
  • OBJECTIVE: To observe the short-term efficacy and safety of Shenqi mixture (SQM) combined with microwave coagulation in treating primary hepatocellular carcinoma (HCC).
  • METHODS: Seventy-two patients with primary HCC of stage II-III, Karnofsky scoring > or = 50 scores and predicted survival period > or = 3 months were selected and randomly assigned into two groups, the treated group and the control group, 36 in each.
  • Comparison of the effective rate between the two groups showed significant difference (P < 0.05). (2) AFP level decreased after treatment in both groups, but the decrement in the treated group was significantly higher than that in the control group (P < 0.01). (3) After treatment, in the treated group, CD3(+), CD4(+), CD4(+)/CD8(+) and NK activity were improved, Karnofsky scores increased and liver function bettered, with these improvements significantly superior to those in the control group (P < 0.01). (4) The improvement in symptoms such as hepatic region pain, fever, weakness, poor appetite and jaundice in the treated group after treatment was also superior to that in the control group (P < 0.01). (5) The 12-month, 18-month and 24-month survival rates were higher and the recurrence rate was lower in the treated group than those in the control group, showing significant difference (P < 0.05).
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Drugs, Chinese Herbal / administration & dosage. Electrocoagulation / methods. Liver Neoplasms / drug therapy. Microwaves / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Leukocyte Count. Liver Function Tests. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150196.001).
  • [ISSN] 1672-0415
  • [Journal-full-title] Chinese journal of integrative medicine
  • [ISO-abbreviation] Chin J Integr Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / alpha-Fetoproteins
  •  go-up   go-down


80. Chan KY, Lai PB, Squire JA, Beheshti B, Wong NL, Sy SM, Wong N: Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Mod Pathol; 2006 Dec;19(12):1546-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma.
  • Molecular characterizations of hepatocellular carcinoma have indicated frequent allelic losses on chromosomes 4q, 8p, 16q and 17p, where the minimal deleted regions have been further defined on 4q12-q23, 4q31-q35, 8p21-p22, 16q12.1-q23.1 and 17p13.
  • Despite these regions are now well-recognized in early liver carcinogenesis, few underlying candidate genes have been identified.
  • In an effort to define affected genes within common deleted loci of hepatocellular carcinoma, we conducted transcriptional mapping by high-resolution cDNA microarray analysis.
  • In 20 hepatocellular carcinoma cell lines and 20 primary tumors studied, consistent downregulations of novel transcripts were highlighted throughout the entire genome and within sites of frequent losses.
  • In primary hepatocellular carcinoma examined, a significant repression of MT1G by more than 100-fold was indicated in 63% of tumors compared to the adjacent nonmalignant liver (P = 0.0001).
  • In summary, transcriptional mapping by microarray indicated a number of previously undescribed downregulated genes in hepatocellular carcinoma, and highlighted potential candidates within common deleted regions.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Deletion. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Down-Regulation. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis


81. Abbasi A, Butt N, Bhutto AR, Gulzar K, Munir SM: Hepatocellular carcinoma: a clinicopathological study. J Coll Physicians Surg Pak; 2010 Aug;20(8):510-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma: a clinicopathological study.
  • OBJECTIVE: To describe the clinico-pathological and radiological profile of hepatocellular carcinoma.
  • METHODOLOGY: All consecutive patients suspected of having hepatocellular carcinoma (HCC), were admitted and included in this study.
  • Patients with primary carcinoma elsewhere in the body, metastatic in the liver, fibrolamellar carcinoma and benign tumours were excluded from the study.
  • RESULTS: There were 82 patients with hepatocellular carcinoma including 58 males and 24 females, with male to female ratio of 2.8:1.
  • Tumour size was larger than 50% of liver size in 42 (51.2%) with portal vein thrombosis in 10 (12.19%).
  • According to Okuda staging system 18 patients had stage 1, 50 had stage 2 and 14 had stage 3 hepatocellular carcinoma.
  • CONCLUSION: The mean age of presentation of hepatocellular carcinoma was younger as compared to western countries with potentially large non-resectable lesions.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis B, Chronic / complications. Hepatitis C, Chronic / complications. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20688014.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


82. Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, Yoon SK, Choi IB, Kang KM, Jang HS: Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):1073-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
  • MATERIALS AND METHODS: A total of 47 patients with small unresectable primary hepatocellular carcinoma received hypofractionated stereotactic body radiotherapy (SBRT) using the CyberKnife.
  • The multivariate analysis showed that the only significant parameter associated with the progression of CP class was the total liver volume receiving a dose less than 18 Gy (<18 Gy).
  • The total liver volume receiving <18 Gy should be greater than 800 cm(3) to reduce the risk of the deterioration of hepatic function.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver / radiation effects. Liver Neoplasms / surgery. Radiation Injuries / etiology. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged. Multivariate Analysis. Radiotherapy Dosage. Tumor Burden

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20207492.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS: Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol; 2010 Jul;21(7):1024-30
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization.
  • PURPOSE: To determine the effects of primary chemoembolization on the health-related quality of life (HRQOL) of patients with hepatocellular carcinoma (HCC).
  • CONCLUSIONS: Patients with HCC are likely to perceive improved mental health during the first 4 months of primary treatment with chemoembolization.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / statistics & numerical data. Liver Neoplasms / epidemiology. Liver Neoplasms / therapy. Quality of Life
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Longitudinal Studies. Male. Maryland / epidemiology. Middle Aged. Prevalence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20621715.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Zhao M, Wang JP, Wu PH, Zhang FJ, Huang ZL, Li W, Zhang L, Pan CC, Li CX, Jiang Y: [Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma]. Zhonghua Yi Xue Za Zhi; 2010 Nov 9;90(41):2916-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the clinical efficacy and survival rate of transarterial chemoembolization (TACE) alone or plus radiofrequency ablation (RFA) in patients with intermediate or advanced stage primary hepatocellular carcinoma (HCC).
  • CONCLUSION: The regimen of TACE plus RFA has the advantages of tumor control, liver function protection and survival extending in the treatment of HCC than TACE alone in intermediate or advanced stage HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation. Embolization, Therapeutic. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21211397.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


85. Soeda J, Yazaki M, Nakata T, Miwa S, Ikeda S, Hosoda W, Iijima M, Kobayashi K, Saheki T, Kojiro M, Miyagawa S: Primary liver carcinoma exhibiting dual hepatocellular-biliary epithelial differentiations associated with citrin deficiency: a case report. J Clin Gastroenterol; 2008 Aug;42(7):855-60
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver carcinoma exhibiting dual hepatocellular-biliary epithelial differentiations associated with citrin deficiency: a case report.
  • We report a 50-year-old male patient with primary liver carcinoma exhibiting dual hepatocellular and biliary epithelial differentiations associated with citrin deficiency (asymptomatic adult-onset type II citrullinemia, CTLN2).
  • Although so far 14 CTLN2 patients with hepatocellular carcinoma have been reported, this report describes a unique case of liver carcinoma showing the features of both hepatocellular and cholangiocellular carcinoma.
  • In addition to the clinical data of the 14 patients reported previously, the findings in our patient suggest that the citrin deficiency might be one of the key disorders causing hepatocellular carcinoma especially at younger ages and can also play an important role in hepatocarcinogenesis of the hepatic progenitor cells, which have the bipotential to differentiate into both hepatocytes and cholangiocytes.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular. Cholangiocarcinoma. Citrullinemia / complications. Liver Neoplasms
  • [MeSH-minor] Cell Differentiation. Hepatectomy. Humans. Liver / cytology. Liver / pathology. Liver Failure / etiology. Male. Middle Aged

  • Genetic Alliance. consumer health - Citrin Deficiency.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18385606.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol; 2009 Mar;16(3):623-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
  • BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma is a very rare form of primary liver cancer containing components of both tumor types.
  • PATIENTS AND METHODS: Of the 2427 patients who underwent hepatectomy or liver transplantation because of a primary hepatic malignancy from January 1989 to July 2006 at the Asan Medical Center, Seoul, Korea, 29 had hepatocellular carcinoma and cholangiocarcinoma as a single mixed or transitional tumor.
  • CONCLUSIONS: Patients with combined hepatocellular carcinoma and cholangiocarcinoma had poor postoperative survival rates.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Liver Transplantation. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130133.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Bosch FX, Ribes J, Cléries R, Díaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis; 2005 May;9(2):191-211, v
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of hepatocellular carcinoma.
  • Year 2000 estimates of the incidence of cancer indicate that primary liver cancer remains the fifth most common malignancy in men and the eighth in women.
  • Changes in incidence among migrant populations underline the predominant role of environmental factors in the etiology of primary liver cancer.
  • In high-risk countries, the early cases of primary liver cancer occur already at ages 20 and above, underlying the impact of viral exposures early in life.
  • In countries at low risk, primary liver cancer is rare before the 50s, translating the impact of late exposures with moderate risks and long latency intervals.
  • The incidence of primary liver cancer is increasing in several developed countries including the United States, and the increase will likely continue for several decades.
  • The variability of primary liver cancer incidence is largely explained by the distribution and the natural history of the hepatitis B and C viruses.
  • The attributable risk estimates for the combined effects of these infections account for well over 80% of liver cancer cases worldwide.
  • Primary liver cancer is the first human cancer largely amenable to prevention using hepatitis B virus vaccines and screening of blood and blood products for hepatitis B and C viruses.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / epidemiology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Alcoholism / epidemiology. Female. Global Health. Hepatitis C, Chronic / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Registries. Risk Factors. Sex Distribution. Smoking / epidemiology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15831268.001).
  • [ISSN] 1089-3261
  • [Journal-full-title] Clinics in liver disease
  • [ISO-abbreviation] Clin Liver Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


88. Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH: A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med; 2008 Dec;49(12):1912-21
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
  • Because (18)F-FDG PET has insufficient sensitivity for the detection of hepatocellular carcinoma (HCC), (11)C-acetate PET has been proposed as another technique for this use.
  • We prospectively evaluated the value of PET/CT using these 2 tracers for the detection of primary and metastatic HCC.
  • METHODS: One hundred twelve patients (99 with HCC, 13 with cholangiocellular carcinoma) underwent biopsy and (18)F-FDG and (11)C-acetate PET/CT.
  • RESULTS: The overall sensitivities of (18)F-FDG, (11)C-acetate, and dual-tracer PET/CT in the detection of 110 lesions in 90 patients with primary HCC were 60.9%, 75.4%, and 82.7%, respectively.
  • In analysis based on biopsied lesions, the sensitivity of (18)F-FDG PET/CT was 64.4% for primary HCC and 84.4% for (11)C-acetate PET/CT.
  • CONCLUSION: The addition of (11)C-acetate to (18)F-FDG PET/CT increases the overall sensitivity for the detection of primary HCC but not for the detection of extrahepatic metastases. (18)F-FDG, (11)C-acetate, and dual-tracer PET/CT have a low sensitivity for the detection of small primary HCC, but (18)F-FDG PET/CT has a relatively high sensitivity for the detection of extrahepatic metastases of HCC.
  • [MeSH-major] Acetates. Carbon. Carcinoma, Hepatocellular. Fluorodeoxyglucose F18. Liver Neoplasms / diagnosis. Liver Neoplasms / mortality. Positron-Emission Tomography / statistics & numerical data. Tomography, X-Ray Computed / statistics & numerical data
  • [MeSH-minor] Adult. Female. Humans. Incidence. Korea / epidemiology. Male. Middle Aged. Prognosis. Prospective Studies. Radiopharmaceuticals. Reproducibility of Results. Risk Assessment / methods. Risk Factors. Sensitivity and Specificity. Subtraction Technique / statistics & numerical data. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997056.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 0 / Radiopharmaceuticals; 0 / carbon-11 acetate; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7440-44-0 / Carbon
  •  go-up   go-down


89. Jung G, Breuer J, Poll LW, Koch JA, Balzer T, Chang S, Mödder U: Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol; 2006 Feb;47(1):15-23
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA.
  • PURPOSE: To evaluate the ability of contrast-enhanced magnetic resonance imaging (MRI) with Gd-EOB-DTPA in comparison with non-enhanced imaging and spiral computed tomography (CT) to provide additional information for classification and characterization of hepatocellular carcinoma.
  • MATERIAL AND METHODS: Forty patients with histopathology-proven hepatocellular carcinoma were selected for this subgroup analysis from a phase-III multicenter study in 235 patients with known or suspected liver lesions.
  • The primary analysis was comparison of the proportion of hepatocellular carcinoma correctly classified and characterized by combined pre-/post-contrast MRI compared with pre-contrast MRI alone or with spiral CT.
  • A non-significant trend in favor of Gd-EOB-DTPA-enhanced MRI with regard to characterization of hepatocellular carcinoma was found, although the CT scans were not optimized as the MRI scans.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Contrast Media / administration & dosage. Gadolinium DTPA. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Europe. Female. Humans. Image Enhancement / methods. Liver / pathology. Liver / radiography. Male. Middle Aged. Observer Variation. Prospective Studies. Reproducibility of Results. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498928.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media; 0 / gadolinium ethoxybenzyl DTPA; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


90. Schott E, Bergk A, Berg T: [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis]. Z Gastroenterol; 2008 Jan;46(1):69-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
  • Liver cirrhosis induced by HBV and HCV infections is the main risk factor for the development of hepatocellular carcinoma (HCC).
  • Therefore, prevention of chronic infection with hepatitis viruses and prevention of the development of cirrhosis are essential for the primary prevention of HCC.
  • Liver transplantation is today the most effective measure of secondary prevention for selected patients with HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / prevention & control. Hepatitis B, Chronic / prevention & control. Hepatitis C, Chronic / prevention & control. Liver Neoplasms / prevention & control
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Child. Female. Hepatitis B Vaccines / administration & dosage. Humans. Liver Cirrhosis / prevention & control. Liver Transplantation. Male. Meta-Analysis as Topic. Primary Prevention. Randomized Controlled Trials as Topic. Risk Factors. Risk-Taking

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18188819.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis B Vaccines
  • [Number-of-references] 110
  •  go-up   go-down


91. Leelawat K, Suksumek N, Leelawat S, Lek-Uthai U: Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients. Southeast Asian J Trop Med Public Health; 2007 Sep;38(5):881-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients.
  • In order to investigate and compare the presence of Helicobacter pylori VacA in primary liver cancer specimens (12 hepatocellular carcinoma and 6 cholangiocarcinoma) and control liver specimens (7 non-primary liver cancer) from Thai patients who underwent liver resection, H. pylori VacA gene was assayed in extracted DNA by real-time polymerase chain reaction.
  • The selected amplicons revealed high homology compared with H. pylori VacA sequence. H. pylori VacA gene was detected in all primary liver cancer specimens and in 71% (5/7) of control liver specimens.
  • [MeSH-major] Bacterial Proteins / genetics. Carcinoma, Hepatocellular / microbiology. Cholangiocarcinoma / microbiology. Helicobacter Infections / microbiology. Helicobacter pylori / genetics. Liver Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Polymerase Chain Reaction / methods. Thailand

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18041306.001).
  • [ISSN] 0125-1562
  • [Journal-full-title] The Southeast Asian journal of tropical medicine and public health
  • [ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / VacA protein, Helicobacter pylori
  •  go-up   go-down


92. Nakajima J, Tanaka M, Matsumoto J, Takeuchi E, Fukami T, Takamoto S: Appraisal of surgical treatment for pulmonary metastasis from hepatocellular carcinoma. World J Surg; 2005 Jun;29(6):715-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appraisal of surgical treatment for pulmonary metastasis from hepatocellular carcinoma.
  • The outcome of pulmonary metastasectomy of hepatocellular carcinoma (HCC) was appraised in this study.
  • They had undergone curative treatment for the primary lesion and were candidates for a pulmonary metastasectomy for complete resection.
  • A Kaplan-Meier analysis showed that multiple lung surgeries and a negative histologic finding of the liver cut surface were favorable characteristics for survival without recurrence.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078127.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Liang SN, Liu LL, Su HY, Feng B, Zhao GS, Xu K: [Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2008 Oct;30(10):790-2
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma].
  • OBJECTIVE: To investigate the cause and treatment as well as prevention measures of rarely occurring severe complications after transcatheter arterial chemoembolization (TACE) for primary hepatic carcinoma.
  • METHODS: 573 consecutive patients with primary hepatic carcinoma underwent a total of 1252 TACE procedures from January 2005 to July 2007.
  • CONCLUSION: The rarely occurring severe complications after transcatheter arterial chemoembolization for primary hepatic carcinoma is correlated with poor hepatic function and portal hypertension before therapy, overdose and reflux of chemotherapeutic agents or allotopic chemoembolism, etc.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Gastrointestinal Hemorrhage / etiology. Liver Failure / etiology. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Hepatic Encephalopathy / etiology. Humans. Iodized Oil / administration & dosage. Iodized Oil / adverse effects. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Pulmonary Embolism / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173817.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; 8001-40-9 / Iodized Oil; U3P01618RT / Fluorouracil
  •  go-up   go-down


94. Arista-Nasr J, Fernández-Amador JA, Martínez-Benítez B, de Anda-González J, Bornstein-Quevedo L: Neuroendocrine metastatic tumors of the liver resembling hepatocellular carcinoma. Ann Hepatol; 2010 Apr-Jun;9(2):186-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine metastatic tumors of the liver resembling hepatocellular carcinoma.
  • Certain neuroendocrine tumors (NET) metastasized to the liver can resemble hepatocellular carcinoma (HCC) in cytological needle biopsy.
  • From a total of 285 needle biopsies with primary or metastasized hepatic neoplasms, seven cases were selected originally diagnosed as HCC or HCC vs. NET metastasized to the liver.
  • Fourteen needle biopsies of hepatocellular carcinomas were also studied for comparative purposes.
  • In all of these neoplasms the diagnosis of endocrine tumor was confirmed by immunohistochemical studies and the following information was recorded: age, sex, radiological alterations, primary site of the NET, and follow-up.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver / pathology. Liver Neoplasms / secondary. Neuroendocrine Tumors / secondary
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Mexico. Middle Aged. Predictive Value of Tests. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526014.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


95. Salmi A, Turrini R, Lanzani G, Viviani G, Zappella A, Savio A, Pirali F: Long-term effectiveness of radiofrequency ablation for hepatocellular carcinoma of 3.5 cm or less. Hepatogastroenterology; 2008 Jan-Feb;55(81):191-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effectiveness of radiofrequency ablation for hepatocellular carcinoma of 3.5 cm or less.
  • BACKGROUND/AIMS: Hepatocellular carcinoma is one of the leading causes of death for cirrhosis, and patients are often not eligible for surgery.
  • To evaluate the effectiveness of radiofrequency ablation in single (less than 3.5cm in diameter) or multiple nodules (up to 3, sized less than 3cm) in respect of acceptability, applicability, primary ablation rate, local recurrence, complications, and long-term patients outcome.
  • Primary complete ablation was obtained in 83.7% of nodules (87.1% of patients), and in a significantly higher rate for nodules up to 2cm (91.3%; p<0.013).
  • CONCLUSIONS: Radiofrequency ablation has great acceptability and applicability, and is a safe and effective treatment to be used after sonographic screening for small hepatocellular carcinomas.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Protocols. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507105.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


96. Ha BY, Ahmed A, Sze DY, Razavi MK, Simpson N, Keeffe EB, Nguyen MH: Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Aliment Pharmacol Ther; 2007 Sep 15;26(6):839-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion.
  • BACKGROUND: Transcatheter arterial chemoembolization (TACE) has become one of the most common treatments for unresectable hepatocellular carcinoma.
  • Primary outcomes were tumour response and survival rates.
  • RESULTS: Only seven patients were hospitalized for more than 24 h after the procedure, and only three patients had worsening of liver function within 30 days of TACI.
  • Following adjustment for age, gender, ethnicity and aetiology of liver diseases, independent predictors of poor survival were Child's class B/C [Hazard Ratio (HR) = 1.69, P = 0.024] and TNM IV staging (HR = 1.63, P = 0.014).
  • CONCLUSIONS: TACI appears to be safe and effective for unresectable hepatocellular carcinoma with TNM stage I-III; randomized controlled trials are needed to compare TACI to TACE.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Chemoembolization, Therapeutic / methods
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Sex Factors. Survival Rate. Treatment Outcome. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17767468.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM: Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer; 2008;8:351
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.
  • BACKGROUND: The objectives of this retrospective study was to evaluate the efficacy of stereotactic body radiation therapy (SBRT) for small non-resectable hepatocellular carcinoma (HCC) and SBRT combined with transarterial chemoembolization (TACE) for advanced HCC with portal vein tumor thrombosis (PVTT).
  • We studied 32 HCC lesions, where 23 lesions (22 patients) were treated targeting small non-resectable primary HCC, and 9 lesions (9 patients) targeting PVTT using the Cyberknife.
  • CONCLUSION: SBRT for small HCC and SBRT combined with TACE for advanced HCC with PVTT showed feasible treatment modalities with minimal side effects in selected patients with primary HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / surgery. Liver Neoplasms / therapy. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):81-7 [10924975.001]
  • [Cites] Hepatology. 2008 Jan;47(1):71-81 [18027884.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):164-70 [11134209.001]
  • [Cites] Eur J Ultrasound. 2001 Jun;13(2):149-58 [11369526.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jun;16(6):660-5 [11422619.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):522-31 [11872300.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1609-19 [12016426.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):150-5 [12182985.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):140-6; discussion 146-7 [12493111.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):113-9 [12909223.001]
  • [Cites] Radiology. 1983 Aug;148(2):397-401 [6306721.001]
  • [Cites] Radiother Oncol. 1983 Nov;1(2):187-91 [6680223.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):657-64 [18172187.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1425-34 [1938550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1249-56 [7713786.001]
  • [Cites] Scand J Gastroenterol. 1997 Jun;32(6):598-603 [9200294.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1578-83 [9620330.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3 [16168826.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):273-8 [16183481.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7391-400 [16437707.001]
  • [Cites] Jpn J Clin Oncol. 2006 Mar;36(3):154-8 [16520355.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1653-63 [16541431.001]
  • [Cites] Acta Oncol. 2006;45(7):961-5 [16982564.001]
  • [Cites] J Clin Oncol. 2007 Mar 10;25(8):938-46 [17350942.001]
  • [Cites] J Am Coll Radiol. 2007 Aug;4(8):563-5 [17660122.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1187-95 [11072178.001]
  • (PMID = 19038025.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2615783
  •  go-up   go-down


98. Zhang K, Kokudo N, Hasegawa K, Arita J, Tang W, Aoki T, Imamura H, Sano K, Sugawara Y, Makuuchi M: Detection of new tumors by intraoperative ultrasonography during repeated hepatic resections for hepatocellular carcinoma. Arch Surg; 2007 Dec;142(12):1170-5; discussion 1176
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of new tumors by intraoperative ultrasonography during repeated hepatic resections for hepatocellular carcinoma.
  • OBJECTIVE: To evaluate the efficacy of intraoperative (IO) ultrasonography (US) as compared with other imaging modalities on the primary and repeated hepatectomies for hepatocellular carcinoma.
  • PATIENTS: From January 6, 1995, to December 26, 2002, 430 patients underwent 555 operations for hepatocellular carcinoma.
  • MAIN OUTCOME MEASURES: New tumors detected by IOUS at the primary and second hepatectomies were analyzed.
  • Intraoperative US detected 56 new tumors in 30 cases (7.0%) at the primary hepatectomy and 13 new tumors in 8 cases (7.3%) at the second hepatectomy.
  • The mean +/- SD tumor sizes were 8.7 +/- 3.8 mm and 9.0 +/- 5.2 mm at the primary and second resections, respectively.
  • The preoperative surgical plan was changed owing to the IOUS findings alone in 24 cases (5.6%) at the primary hepatectomy and in 7 cases (6.4%) at the second.
  • Although recurrence was frequent in patients with new tumors at the primary hepatectomy, long-term survival after appropriate treatment for recurrence was similar to that of patients without new tumors.
  • [MeSH-major] Carcinoma, Hepatocellular / ultrasonography. Hepatectomy. Liver Neoplasms / ultrasonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Period. Male. Middle Aged. Reoperation. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086983.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Verhoef C, Holman FA, Hussain SM, de Man RA, de Wilt JH, IJzermans JN: Resection of extrahepatic hepatocellular carcinoma metastasis can result in long-term survival. Acta Chir Belg; 2005 Sep-Oct;105(5):533-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of extrahepatic hepatocellular carcinoma metastasis can result in long-term survival.
  • Hepatocellular carcinoma (HCC) is one of the most common primary cancers in the world and the third most common cause of cancer mortality world-wide.
  • The prognosis is mainly determined by the underlying liver disease and recurrent rates.
  • In the Western World, up to 30% of the patients with HCC have a non-cirrhotic liver.
  • The role of resection in case of intrahepatic recurrences is widely accepted, particularly in the non-cirrhotic liver.
  • We present two patients with HCC in a non-cirrhotic liver with extrahepatic recurrences and long-term survival after resection.
  • The corresponding literature support an aggressive approach in case of extrahepatic HCC recurrence in selected cases: resectable metastasis, preserved liver function, absence of intracranial metastasis and control of the primary tumour.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Carcinoma, Hepatocellular / surgery. Kidney Neoplasms / secondary. Kidney Neoplasms / surgery. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver / physiology. Male. Prognosis. Recurrence. Survival. Thoracic Wall / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315842.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


100. Lee LT, Huang HY, Huang KC, Chen CY, Lee WC: Age-period-cohort analysis of hepatocellular carcinoma mortality in Taiwan, 1976-2005. Ann Epidemiol; 2009 May;19(5):323-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-period-cohort analysis of hepatocellular carcinoma mortality in Taiwan, 1976-2005.
  • PURPOSE: Hepatocellular carcinoma (HCC) is one of the most common malignant primary liver tumors worldwide.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Female. Hepatitis B Vaccines / administration & dosage. Humans. Male. Middle Aged. Mortality / trends. Sex Factors. Taiwan / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19362276.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down






Advertisement